UCLA joins international effort to study genetics of schizophrenia in deletion syndrome patients

UCLA has joined an international consortium to investigate the high rates of schizophrenia and other neuropsychiatric disorders in those who are affected with Chromosome 22q11.2 deletion syndrome, a disorder caused by the deletion of a small piece of chromosome number 22.   A multisystem disorder, Chromosome 22q11.2 deletion syndrome can also include developmental delays and developmental and behavioral differences across the life span.   The International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome is a large-scale effort involving 22 institutions in North America, including UCLA, as well as several across Europe, Australia and South America. The collaborative effort has been awarded $12 million over four years from the National Institute of Mental Health.   Occurring in approximately one out of every 4,000 live births, 22q11.2 deletion syndrome has many possible signs and symptoms that can affect almost any part of the body. These can include heart abnormalities that often require surgery in newborns, trouble fighting infection due to a poorly functioning immune system, and significant feeding and swallowing issues.   While a few individuals with the syndrome will not experience any ofthese medical issues, the majority of children have developmental delays. These can include delayed acquisition of motor milestones, learning disabilities and significant delays in the emergence of language. Moreover, a  substantial number of children...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news